Pain Management

Officials with the FDA have approved Zimhi 5 mg/0.5 mL, a high-dose naloxone injection product, for use in the treatment of opioid overdose.

In an interview with Pharmacy Times®, Mitchell Barnett, PharmD, MS, associate director of the Iowa Prescription Monitoring Program for the Iowa Board of Pharmacy, and Mylo Wells, PharmD, owner of Wells Hometown Drug, discuss Iowa’s new drug disposal kit program and the impact it could have on the opioid epidemic.

Symptoms of fibromyalgia often begin after an event, such as physical trauma, surgery, infection, or significant psychological stress.

Significant reductions in mean monthly migraine days compared with placebo were seen as early as weeks 1 through 4 in the clinical trial program for atogepant.

Schedule I drugs, substances, or chemicals are defined as medications with no currently accepted medical use and a high potential for abuse.

Funded by a grant from the National Institutes of Health, this trial is intended to test the safety and efficacy of a vaccine designed to selectively prevent the euphoric and toxic effects of oxycodone.

September is National Recovery Month, so Pharmacy Times interviewed Rich Dion, PharmD, of Wolters Kluwer, Health, on the critical role of the hospital pharmacist in ongoing efforts to fight the opioid epidemic.

Pharmacists can be instrumental in reducing the main challenges in opioid use disorder—namely supply, demand, and harm.

The AHA worked with a team of leading health authorities to develop the advisory, which highlights recommendations, algorithms, and guidance for health care professionals and researchers who specialize in heart and brain health.

Study findings could influence how drug developers consider how opioid drugs cause tolerance and respiratory depression, and it suggests an alternative approach to developing safer analgesics.

Pharmacists carry a unique responsibility in the battle that has claimed 500,000 lives in the past 2 decades.

For the study, approximately 20,000 people were followed over a span of 4 years, which showed that reports of marijuana use peaked at 9% for patients with cancer versus 14% among those with no cancer history.

Nicholas Mathews, co-founder of Stillwater Behavioral Health, discusses how pharmacists can respond to the identification of potentially problematic opioid prescription practices at sober-living facilities.

Thomas Maggio, MBA, public affairs and engagement manager at AACP, discussed his presentation assessing the Opioid-Related Activity Database and its impact in showing the efforts of pharmacists and student pharmacists to fight the opioid epidemic.

Advice to community pharmacists and patients who suffer from migraine on strategies that can improve quality of life and be used to navigate the care continuum.

Red flags that would prompt a pharmacist to refer a patient with migraine to be evaluated by a physician.

What community pharmacists need to know about migraine treatment and their role in educating and managing patients.

An overview of CGRP antagonists approved as preventive therapy for migraine and recommendations for appropriate dosing and administration to patients.

Factors that need to be considered when determining patient candidacy for over-the-counter herbal products and nutritional supplements available as preventive therapy for migraine and recommendations for educating patients about their use.

Researchers hypothesized that people may look for the UV-B type of UV light because they are unaware of their need for endorphins.

Preventive therapies available for patients who require migraine prophylaxis and factors that impact treatment selection.

Jennifer L. Mazan, PharmD, describes the role of CGRP antagonists as acute migraine treatment and shares considerations for selecting and using these therapies.

As the first point of contact at many pharmacies, technicians can often see whether a patient has been prescribed an opioid or other monitored substances.

Special considerations for counseling patients and prescribing lasmiditan, a targeted 5-HT1F therapy approved as acute migraine treatment.

Timothy Smith, MD, RPh, FACP, AQH, describes goals of therapy for the acute treatment of migraine and reacts to current treatment limitations associated with available drug therapies.